ClinicalTrials.gg
CompletedNCT06753955Updated Apr 27, 2026

Phase 1 Study of ART5803 Safety and PK After IVIG in Healthy Participants

A Phase 1 interventional study of ART5803 and Intravenous immunoglobulin (IVIG) in Autoimmune Encephalitis Caused by N-Methyl D-Aspartate Receptor Antibody, Autoimmune Encephalitis Caused by N-Methyl D-Aspartate Receptor Antibody (Disorder) and Autoimmune Encephalitis, sponsored by Arialys Therapeutics. Completed at 1 site in Australia. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-27.

Sponsored by Arialys Therapeutics · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
7
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This study will evaluate the safety, tolerability, and pharmacokinetics (PK) of ART5803 following IVIG administration in healthy participants to investigate the potential interactions between ART5803 and IVIG

Read the detailed description

Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis is one of the most common causes of autoimmune encephalitis. The disease is caused by the development of autoantibodies against the amino (N)-terminal domain (NTD) of the NMDAR subunit 1 (NR1) that bind and cross link the receptors, leading to receptor internalization and loss of function.

Arialys has developed a monovalent (one-armed) antibody, ART5803, that binds to the NTD of the NMDAR NR1 subunit without causing NMDAR inhibition, activation, or receptor internalization, while simultaneously blocking the ability of the pathogenic anti-NMDAR autoantibodies to bind to the receptor.

In treating anti-NMDAR encephalitis, intravenous immunoglobulin (IVIG) is commonly administered in conjunction with corticosteroids. Consequently, it is anticipated that IVIG may be administered to the target population prior to ART5803. IVIG has a long half-life and competitive binding of IVIG to the neonatal fragment crystallization receptor (FcRn) may result in FcRn saturation. This can potentially lead to increased clearance and/or impaired tissue distribution of ART5803 and decrease the cerebrospinal fluid (CSF) exposure to ART5803 through competition on FcRn at the blood-brain barrier (BBB).

02

Conditions studied

  • Autoimmune Encephalitis Caused by N-Methyl D-Aspartate Receptor Antibody
  • Autoimmune Encephalitis Caused by N-Methyl D-Aspartate Receptor Antibody (Disorder)
  • Autoimmune Encephalitis

Keywords

  • Anti-N-methyl-D-aspartate receptor (NMDAR)
  • Encephalitis
  • Anti-N-methyl-D-aspartate receptor (NMDAR) Encephalitis
  • Intravenous immunoglobulin (IVIG)
03

In context

Autoimmune Diseases of the Nervous System

123 studies on the registry are indexed under Autoimmune Diseases of the Nervous System; 59 are open to participants now.

This study's enrollment of 7 is below the median of 40 across 63 interventional studies indexed under Autoimmune Diseases of the Nervous System.

Browse Autoimmune Diseases of the Nervous System studies →

Lead sponsor

Arialys Therapeutics is the lead sponsor of 2 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The participant must be willing and able to provide written, signed after the nature of the study has been explained and prior to any research-related procedures.
  2. The participant is a male or female, 18 to 65 years of age (inclusive) at the time of informed consent, and has a (BMI) between 18 and 32 kg/m2 (inclusive) and a weight not exceeding 100 kg.
  3. The participant is healthy, as determined by medical history, physical examinations, and the clinical Investigator's judgment.
  4. The participant must be willing and able to comply with all study procedures.
  5. Sexually active female participants of and male participants with female partner(s) of childbearing potential must be willing to use a highly effective method of while participating in the study. The contraceptive methods used for male and female participants must be documented in the source documents.
  6. Female participants of childbearing potential must have a negative pregnancy test at Screening and be willing to have additional pregnancy tests during the study. Females considered not of childbearing potential include those who are surgically sterile (surgical bilateral oophorectomy, bilateral salpingectomy, or hysterectomy) confirmed by medical history or are (i.e., no menstrual bleeding for more than 12 months without an alternative medical cause and confirmation with more than 1 follicle-stimulating hormone measurement of at least > 40 IU/L [or higher per local institutional guidelines]).Women of non-childbearing potential are not required to use any contraceptive method.
  7. Male participants with female partners of childbearing potential must agree to use highly effective methods of contraception, from study drug administration until at least 90 days after the last study drug administration.
  8. Male participants must agree not to donate sperm, and female participants must agree not to donate eggs for the duration of the study and until at least 90 days after the last study drug administration.
  9. Participants must agree not to donate blood for at least 3 months after the end-of-study (EOS) visit.

Exclusion criteria

Exclusion Criteria:

  1. The participant is pregnant or breastfeeding at Screening or planning to become pregnant (self or partner) at any time during the study.
  2. The participant has used an product or medical device within 30 days of Screening or for significant illness, such as cardiovascular, neurologic, pulmonary, hepatic, renal, metabolic, gastrointestinal, urologic, immunologic, endocrine, or psychiatric disease or disorder, or other abnormality, which may interfere with the evaluation or administration of the study drug, interpretation of participant safety or study results, or would make participation in the study an unacceptable risk including any significant acute or chronic medical condition. The Investigator is responsible for assessing the clinical significance of findings from health assessments and evaluations; however, consultation with the medical monitor may be warranted.
  3. Has a concurrent disease or condition that, in the view of the Principal Investigator, places the participant at high risk of poor treatment compliance or of not completing the study, or would interfere with study participation or would affect safety. Participants with fully resolved childhood asthma with no reoccurrences or hospitalizations remain eligible for participation.
  4. The participant is a regular smoker (cigarettes, e-cigarettes, and vaping included), defined as smoking daily. Participants who are non-daily smokers (up to ≤5 cigarettes per week [or vaping or e-cigarette equivalent]) are permitted to participate in the study and must agree to refrain from smoking during the in-patient stays.
  5. The participant has a to undergo LP, including (INR) >1.4 or other coagulopathy, cell count of \<120,000/µL, infection at the desired LP site, current use of anti-coagulant medication except for low dose acetylsalicylic acid, degenerative arthritis, spinal scoliosis, back surgery, suspected increased intracranial pressure on history or neurologic examination, non-communicating hydrocephalus or intracranial mass, or prior history of spinal mass or trauma.
  6. The participant has a severe drug allergic history or anaphylaxis to 2 or more food products or medicines (including known sensitivity to acetaminophen/paracetamol, diphenhydramine or equivalent antihistamine, methylprednisolone or equivalent , or lidocaine).
  7. The participant has a known history of allergy or reaction to any component of the investigational agent formulation or IVIG or any of its components, or a history of anaphylaxis or severe systemic reaction to blood products or following any biologic therapy.
  8. The participant has a history of alcohol abuse or drug addiction in the past 12 months.
  9. The participant has undergone significant trauma or major surgery within 4 weeks of Screening.
  10. The participant has had a vaccination with live virus, attenuated live virus, or any live viral components within 2 weeks prior to study drug administration or is planning to receive these vaccines at any time during the study and up to 8 weeks following the last study drug administration.
  11. The participant has ANY of the following abnormalities in clinical laboratory tests at Screening, as assessed by the study-specific laboratory and confirmed by a single repeat if deemed necessary:

    1. Serum creatinine level more than 1.25× (ULN) or an estimated value \<80 mL/min/1.73 m2 calculated with the Chronic Kidney Disease Epidemiology Collaboration formula and more than trace protein in urine.
    2. Total , (AST) or alanine aminotransferase (ALT) values more than >2×ULN. Note: participants with a history of Gilbert's syndrome are excluded from participation in the study.
    3. Hematological or coagulation values outside the normal reference range for local laboratory results unless regarded as not .
    4. Confirmed positive test for serology (hepatitis B surface antigen and core antibody) and/or polymerase chain reaction.
    5. Values indicating a deficiency of immunoglobulin A (IgA) or anti-IgA antibodies.
  12. The participant has a 12-lead demonstrating an abnormal interval by Fridericia (QTcF) (>450 ms for males, >470 ms for females) or a QRS interval >120 ms. If QTcF is abnormal (>450 ms for males, >470 ms for females) or a QRS interval >120 ms, the ECG should be repeated 2 more times, and the average of the 3 QTcF or QRS interval values (i.e., the initial reading plus 2 repeats for a total of 3 readings, averaged) should be used to determine the participant's eligibility.
  13. The participant has Investigator determined coronavirus disease of 2019 (COVID 19) within 4 weeks prior to Day 1, received the COVID-19 vaccine within 2 weeks prior to study drug administration, or plans to receive a COVID-19 vaccine within 9 weeks after study drug administration. Regional and site COVID-19 testing policies should be followed throughout the study.
  14. The participant has a positive urine or blood result for drugs of abuse (defined as any illicit drug use) at Screening or Check-in (Day -1).
  15. The participant has received any NMDAR modulator other than the study drug (e.g., ketamine, memantine, dextromethorphan, amantadine, ifenprodil, phencyclidine [PCP], acamprosate, D-cycloserine) or IVIG from within 30 days or 5 half lives of the other NMDAR modulator or IVIG (whichever is longer) of study drug administration until the end of the study.
  16. The participant has a known history of primary immunodeficiency (congenital or acquired) or an underlying condition such as infection.
  17. The participant has had a bacillus of Calmette and Guérin vaccine within 1 year of enrollment.
  18. The participant has a history of severe depression, bipolar disease, or schizophrenia.
  19. The participant has a risk of suicide per the C-SSRS (a score of 4 or 5 on ideation or any suicidal behavior) or, according to the Investigator's clinical judgment, has made a suicide attempt in the previous 6 months, or has a history of deliberate self-harm in the past 6 months.
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
7 participants (actual)

Study arms

  • Other
    Cohort 1

    IVIG IV infusion (not experimental) followed by ART5803 IV infusion (experimental)

    Drug: ART5803 · Drug: Intravenous immunoglobulin (IVIG)

Interventions

  • A monovalent (one-armed) antibody, that binds to the NTD of the NMDAR NR1 subunit without causing NMDAR inhibition, activation, or receptor internalization, while simultaneously blocking the ability of the pathogenic anti-NMDAR autoantibodies to bind to the receptor.

  • Administered as background treatment prior to the investigational product

06

What researchers measure

Primary outcomes

  1. Safety will be assessed by the incidence and severity of treatment-emergent adverse events (TEAEs)

    ART5803 safety, as measured by the number of treatment emergent adverse events

    Time frame: 13 Weeks

  2. Safety will be assessed by clinically significant changes in physical and neurological examination findings

    ART5803 safety, will be assessed by clinically significant changes in physical and neurological examination findings

    Time frame: 13 Weeks

  3. Safety by assessed by clinically significant changes in vital signs

    ART5803 safety, will be assessed by clinically significant changes in vital signs including systolic and diastolic blood pressure, pulse rate, respiration rate, and body temperature

    Time frame: 13 Weeks

  4. Safety by assessed by clinically significant changes in clinical laboratory outcomes

    ART5803 safety, will be assessed by clinically significant changes in clinical laboratory outcomes including clinical chemistry, hematology, coagulation, and urinalysis

    Time frame: 13 Weeks

  5. Safety by assessed by clinically significant changes in 12-lead ECG findings

    ART5803 safety, will be assessed by clinically significant changes 12-lead ECG findings

    Time frame: 13 Weeks

  6. Safety by assessed by clinically significant changes in concomitant medications

    ART5803 safety, will be assessed by clinically significant changes in concomitant medications

    Time frame: 13 Weeks

  7. Safety by assessed by clinically significant changes in presence of anti-drug antibodies (ADAs)

    ART5803 safety, will be assessed by clinically significant changes in presence of anti-drug antibodies (ADAs)

    Time frame: 13 Weeks

  8. Safety will be assessed by incidence of dose-limiting toxicity (DLTs)

    ART5803 safety, will be assessed by incidence of dose-limiting toxicity (DLTs)

    Time frame: 13 Weeks

  9. Safety will be assessed by change in suicidal tendency measured by Columbia-Suicide Severity Rating Scale (C-SSRS)

    ART5803 safety, will be assessed by change in suicidal tendency as measured by the incidence of positive responses (Yes) to Item 4 or 5 on the Columbia-Suicide Severity Rating Scale (C-SSRS)

    Time frame: 13 Weeks

  10. To assess the pharmacokinetics (PK) of single IV dose of ART5803 following prior doses of IVIG

    To characterize and compare the PK profile of single IV dose of ART5803 following prior doses of IVIG as measured by maximum concentration (Cmax)

    Time frame: 13 Weeks

  11. To assess the pharmacokinetics (PK) of single IV dose of ART5803 following prior doses of IVIG

    To characterize and compare the PK profile of single IV dose of ART5803 following prior doses of IVIG as measured by last time point with measurable concentration (Clast)

    Time frame: 13 Weeks

  12. To assess the pharmacokinetics (PK) of single IV dose of ART5803 following prior doses of IVIG

    To characterize and compare the PK profile of single IV dose of ART5803 following prior doses of IVIG as measured by minimum concentration (Cmin)

    Time frame: 13 Weeks

  13. To assess the pharmacokinetics (PK) of single IV dose of ART5803 following prior doses of IVIG

    To characterize and compare the PK profile of single IV dose of ART5803 following prior doses of IVIG as measured by time at which Cmax is observed (tmax)

    Time frame: 13 Weeks

  14. To assess the pharmacokinetics (PK) of single IV dose of ART5803 following prior doses of IVIG

    To characterize and compare the PK profile of single IV dose of ART5803 following prior doses of IVIG as measured by time at which Clast is observed (tlast)

    Time frame: 13 Weeks

  15. To assess the pharmacokinetics (PK) of single IV dose of ART5803 following prior doses of IVIG

    To characterize and compare the PK profile of single IV dose of ART5803 following prior doses of IVIG as measured by area under the curve from time 0 to the last measurable concentration (AUC0-t)

    Time frame: 13 Weeks

  16. To assess the pharmacokinetics (PK) of single IV dose of ART5803 following prior doses of IVIG

    To characterize and compare the PK profile of single IV dose of ART5803 following prior doses of IVIG as measured by area under the curve from time 0 extrapolated to infinity (AUC0-∞)

    Time frame: 13 Weeks

  17. To assess the pharmacokinetics (PK) of single IV dose of ART5803 following prior doses of IVIG

    To characterize and compare the PK profile of single IV dose of ART5803 following prior doses of IVIG as measured by the half-life (t½)

    Time frame: 13 Weeks

  18. To assess the pharmacokinetics (PK) of single IV dose of ART5803 following prior doses of IVIG

    To characterize and compare the PK profile of single IV dose of ART5803 following prior doses of IVIG as measured by the volume of distribution (Vd)

    Time frame: 13 Weeks

  19. To assess the pharmacokinetics (PK) of single IV dose of ART5803 following prior doses of IVIG

    To characterize and compare the PK profile of single IV dose of ART5803 following prior doses of IVIG as measured by by clearance (CL)

    Time frame: 13 Weeks

  20. To assess the pharmacokinetics (PK) of single IV dose of ART5803 following prior doses of IVIG

    To asses the CSF/serum ratio of ART5803 at multiple time points

    Time frame: 13 Weeks

Secondary outcomes

  1. To assess the immunogenicity of a single IV dose of ART5803 following prior doses of IVIG

    To assess the incidence of anti-drug antibodies (ADAs) in serum from a single IV dose of ART5803 following prior doses of IVIG

    Time frame: 13 Weeks

Other outcomes

  1. To assess changes in cognition as measured by the Mini-Mental State Examination (MMSE) after a single IV dose of ART5803 following prior doses of IVIG

    To assess the change in MMSE total scores from baseline

    Time frame: 13 Weeks

  2. To assess changes in cognition as measured by the Trial Making Test Part A & B (TMT-A and TMT-B) after a single IV dose of ART5803 following prior doses of IVIG

    To assess the change in TMT-A and TMT-B total scores from baseline

    Time frame: 13 Weeks

07

Study locations

1 site
  • Nucleus Network Pty Ltd
    Melbourne, Victoria 3004, Australia
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2025 to primary completion in Jul 2025, 4 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 23, 2024
First posted
Dec 31, 2024
StartActual
Feb 25, 2025
Primary completionActual
Jul 2, 2025
CompletionActual
Aug 19, 2025
Last update
Apr 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06753955
Lead sponsor
Arialys Therapeutics
Responsible party
Sponsor
First posted
Dec 31, 2024
Start date
Feb 25, 2025
Primary completion
Jul 2, 2025
Completion
Aug 19, 2025
Last update
Apr 27, 2026

Study contacts

Sankalp Gokhale, MD, MBA
study chair · Arialys Therapeutics

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: ART5803

Start the discussion